Solid Biosciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLDB research report →
About the company
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles.
- CEO
- Alexander G. Cumbo
- IPO
- 2018
- Employees
- 100
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $844.55M
- P/E
- -5.56
- P/S
- 0.00
- P/B
- 3.18
- EV/EBITDA
- -2.99
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -74.45%
- ROIC
- -49.76%
- Revenue
- $0 · 0.00%
- Net Income
- $-174,325,000 · -39.80%
- EPS
- $-1.99 · 34.97%
- Op Income
- $-179,206,000
- FCF YoY
- -56.40%
- 52W High
- $10.88
- 52W Low
- $3.79
- 50D MA
- $7.56
- 200D MA
- $6.46
- Beta
- 2.36
- Avg Volume
- 1.63M
Get TickerSpark's AI analysis on SLDB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 22, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 0 |
| Jun 22, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 0 |
| Jun 22, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 0 |
| Jun 22, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 8,178,412 |
| Jun 10, 26 | Nagendran Sukumar | other | 77,500 |
| Jun 10, 26 | SMITH IAN F | other | 77,500 |
| Jun 10, 26 | Ganot Ilan | other | 77,500 |
| Jun 10, 26 | PERCEPTIVE ADVISORS LLC | other | 77,500 |
| Jun 10, 26 | Keresty Georgia | other | 77,500 |
| Jun 10, 26 | Freed Martin I | other | 77,500 |
Our SLDB coverage
Recent articles, reports, and earnings notes.
No research on SLDB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SLDB report →Similar companies
Peers in the same neighborhood.